Pioglitazone is an FDA-approved PPAR-γ agonist drug used to treat diabetes, and it has demonstrated neuroprotective effects in multiple models of central nervous system (CNS) injury. Acute treatment after spinal cord injury (SCI) in rats is reported to suppress neuroinflammation, rescue injured tissues, and improve locomotor recovery. In the current study, we additionally assessed the protective efficacy of pioglitazone treatment on acute mitochondrial respiration, as well as functional and anatomical recovery after contusion SCI in adult male C57BL/6 mice. Mice received either vehicle or pioglitazone (10 mg/kg) at either 15 min or 3 h after injury (75 kdyn at T9) followed by a booster at 24 h post-injury. At 25 h, mitochondria were isolated from spinal cord segments centered on the injury epicenters and assessed for their respiratory capacity. Results showed significantly compromised mitochondrial respiration 25 h following SCI, but pioglitazone treatment that was initiated either at 15 min or 3 h post-injury significantly maintained mitochondrial respiration rates near sham levels. A second cohort of injured mice received pioglitazone at 15 min post injury, then once a day for 5 days post-injury to assess locomotor recovery and tissue sparing over 4 weeks. Compared to vehicle, pioglitazone treatment resulted in significantly greater recovery of hind-limb function over time, as determined by serial locomotor BMS assessments and both terminal BMS subscores and gridwalk performance. Such improvements correlated with significantly increased grey and white matter tissue sparing, although pioglitazone treatment did not abrogate long-term injury-induced inflammatory microglia/macrophage responses. In sum, pioglitazone significantly increased functional neuroprotection that was associated with remarkable maintenance of acute mitochondrial bioenergetics after traumatic SCI. This sets the stage for dose-response and delayed administration studies to maximize pioglitazone's efficacy for SCI while elucidating the precise role that mitochondria play in governing its neuroprotection; the ultimate goal to develop novel therapeutics that specifically target mitochondrial dysfunction.
Introduction
There are approximately 17,000 new traumatic spinal cord injury (SCI) cases in the United States each year yet, despite numerous clinical trials, there are currently no comprehensively accepted therapies to treat the pathophysiology of acute traumatic SCI (Center, 2016; Rabchevsky et al., 2011) . The exception is methylprednisolone sodium succinate (MPSS), the only clinically approved compound reported to show modest efficacy on certain functional outcome measures when administered within the first 8 h after SCI (Bracken, 1990 (Bracken, , 2001 Bracken et al., 1984 Bracken et al., , 1985 Bracken et al., , 1990 Bracken et al., , 1992 Bracken et al., , 1997 . Traumatic SCI is characterized by an initial mechanical insult followed by a series of destructive pathophysiological cascades that disrupt a constellation of biochemical and cellular signaling pathways (Hall and Springer, 2004; McEwen et al., 2011) . Mitochondrial dysfunction is thought to be one of the primary cause/effect components of these secondary events since they are the principal energy producers for the cell, as well as the main site for reactive oxygen/nitrogen species (ROS/RNS) formation which initiate many cell death mechanisms (Finkel, 2001; Patel et al., 2010 Patel et al., , 2012 Sullivan et al., 2005 Sullivan et al., , 2007 Yonutas et al., 2015) . Accordingly, there is emerging evidence that preventing mitochondrial dysfunction acutely with pharmacotherapeutics following experimental neurotrauma results in significant neuroprotection and functional recovery at later stages Patel et al., 2010 Patel et al., , 2012 Patel et al., , 2014 Sauerbeck et al., 2011) .
Pioglitazone is an FDA approved treatment for type-2 diabetes and belongs to a class of drugs called thiazolidinediones (TZDs), which are peroxisome proliferating activating receptor (PPAR) agonists (Michalik et al., 2004; Michalik and Wahli, 1999; Sood et al., 2000) . The three isoforms of PPAR (PPRA-α, PPAR-β/δ, and PPAR-γ) are part of the nuclear receptor superfamily and perform a wide array of tasks, such that their function has not been systematically defined (Berger and Moller, 2002; Michalik and Wahli, 1999; Yonutas and Sullivan, 2013) . Nevertheless, it is widely accepted that PPAR activity plays a critical role in lipid metabolism, modulates expression patterns of pro-inflammatory cytokines, and increases expression of anti-oxidant proteins (Chen et al., 2007; Frazier-Wood et al., 2013; Kapadia et al., 2008; Martin et al., 2012; Sood et al., 2003; Yi et al., 2008) . The TZDs which bind PPAR-γ are particularly germane to SCI therapeutics, notably pioglitazone. Pioglitazone can rapidly cross the blood-brain barrier (Berger and Moller, 2002) and has demonstrated more robust neuroprotection than other TZDs such as rosiglitazone which has higher binding affinity for PPAR-γ (Kapadia et al., 2008; Thal et al., 2011) . This may be due to emerging evidence that pioglitazone's therapeutic effects may also depend on PPAR-independent mechanisms that ameliorate mitochondrial dysfunction and which stem from its interactions with the mitoNEET, an iron-sulfur domain-containing protein (Colca et al., 2004) .
mitoNEET is a protein localized in the brain, liver and skeletal muscles of rodents (Colca et al., 2004) . This finding came long after the discovery that pioglitazone had a binding affinity for the mitochondrial membrane. After further investigation, it was determined that this binding was mediated through a new m-17 kDa protein which was later termed mitoNEET (Colca et al., 2004) . At the time of its discovery, mitoNEET was proposed to be a pivotal protein for mitochondrial metabolism which had the potential of being modulated by pioglitazone. Since its initial discovery, the exact role of mitoNEET in the cell remains uncertain. However, a handful of groups have studied mitoNEET's protein dynamics and suggested one possible role is to be a shuttle protein for the mitochondria (Conlan et al., 2009; Hou et al., 2007; Lin et al., 2007; Paddock et al., 2007) . Pioglitazone binding can then inhibit the transfer of [2Fe-2S] clusters making mitoNEET unable to dimerize and perform its necessary task. Additionally, through the use of mitoNEET knockout mice, it was shown that mitochondria without mitoNEET have a decreased oxidative capacity which suggests that this iron-containing protein may be pivotal in controlling the rate of mitochondrial respiration (Geldenhuys et al., 2011; Kusminski et al., 2012; Pedada et al., 2014; Wiley et al., 2007) . Finally, a recent study has highlighted that mitoNEET is a redox-sensitive protein and can be reduced by biological thiols such as glutathione (GSH), reversing the effect of mitoNEET oxidation (Landry and Ding, 2014) in accordance that GSH precursors can reverse mitochondrial dysfunction and afford neuroprotection following CNS injuries Patel et al., 2014) .
Pioglitazone has been shown to reduce neuroinflammation, restore mitochondrial homeostasis, spare neurons, and promote functional recovery following traumatic brain injury (TBI) (Liu et al., 2017; Sauerbeck et al., 2011; Thal et al., 2011) . However, much of the protection appears to be independent of PPAR, given the concentrations used and the incomplete reversal of protection in the presence of PPAR antagonists, again indicating a potential role for mitoNEET in mediating pioglitazone neuroprotection. Despite its use in TBI, pioglitazone has a limited but promising history of experimental therapeutic application for SCI, studied exclusively in rats (McTigue et al., 2007; Park et al., 2007) . Furthermore, its effects on mitochondrial bioenergetics after SCI remain uncharacterized. While pioglitazone has been shown to preserve mitochondrial function following TBI in mice (Sauerbeck et al., 2011) , it is not known if pioglitazone elicits similar outcomes following SCI. Accordingly, in the current study we assessed the protective efficacy of pioglitazone treatment on mitochondrial bioenergetics acutely and long-term functional recovery and tissue sparing following contusion SCI in mice.
Materials and methods

Animals
Adult male C57BL/6 mice (n = 64) (Jackson Laboratories, Bar Harbor, Maine) were housed in a vivarium at 25°C under a 12 h light/ dark cycle and were allowed access to food and water ad libidum. All experimental procedures occurred during the light cycle. All procedures were approved by and in accordance with the University of Kentucky Institutional Animal Care and Use Committee.
Spinal cord injury surgery and treatments
Before surgery, animals were deeply anesthetized via ketamine (150 mg/kg) and xylazine (10 mg/kg) injection (i.p.). The surgical site was shaved and disinfected with isopropyl alcohol and betadine. A small incision was made on the dorsal surface, and the muscle and subcutaneous tissue overlaying the thoracic spine were retracted. A T9 laminectomy was performed to expose the mid-thoracic spinal cord. Severe contusions were produced using the Infinite Horizons impactor device (75 kdyn; Precision Systems and Instrumentation, LLC, Lexington, KY, USA) as we have described previously (Zhang et al., 2015b) . The hit parameters (mean ± SD) for mice included in final analyses were equivalent between vehicle (n = 19) and pioglitazone (n = 29) treated injury cohorts for impact force [vehicle group (78.26 . Any injured animals with abnormalities in the force vs time curve, which are indicative of bone hits or instability of the spinal cord, were excluded from analysis. For biochemical assessment of mitochondrial integrity, sham mice (n = 7) received laminectomy only and displayed normal hind-limb function post-surgery. The wound was closed with monofilament suturing of the muscle and skin incisions. Afterwards, animals were returned to their home cage placed a heating pad and administered injections (s.c.) of Buprenorphine SR (0.1 mg/kg, Reckitt Benckisser Pharmaceuticals Inc., Richmond, VA) and Baytril (2.5 ml/kg, mixed with 2 ml sterile saline), then allowed to regain consciousness.
Injured mice being assessed for acute mitochondrial respiration (n = 27 total) received an injection (i.p.) of either pioglitazone (10 mg/kg, dissolved in DMSO at 3 mg/ml) at 15 min (n = 9) or 3 h (n = 10), versus vehicle (DMSO) 15 min after injury (n = 7), and they also received a booster of pioglitazone or DMSO at 24 h post-injury, 1 h prior to tissue harvesting. Due to post-surgical complications, one mouse died prior to acute biochemical assessments. Long-term behavioral experiments were carried out using two independent cohorts (n = 30 total). Injured mice received an injection (i.p.) of either 10 mg/kg pioglitazone (n = 10) or 100% DMSO (n = 12) 15 min after injury, and then daily injections (i.p.) of either pioglitazone or DMSO for 5 days post-injury, followed by injection (s.c.) of Baytril (2.5 ml/kg, mixed with 1 ml sterile saline). Manual bladder expression was performed twice daily on injured mice. Data for 8 injured mice are not presented because they were either excluded due to post-injury complications or died. Specifically, three mice were euthanized due to abnormal contusions, one due to severe bladder infection, two due to autophagia, and one mouse died during long-term behavioral experiments for unknown reasons.
Mitochondrial isolation
Mitochondria from sham and injured spinal cords were isolated by modifying our previously reported method (Patel et al., 2009 . At 24 h post-injury, animals were decapitated and a 0.5 cm thoracolumbar spinal cord segment centered on injury site was rapidly dissected from all injured as well as naïve mice and homogenized in an ice-cold dissecting plate containing isolation buffer with 1 mM EGTA (215 mM mannitol, 75 mM sucrose, 0.1% BSA, 20 mM HEPES, 1 mM EGTA, and pH adjusted to 7.2 with KOH). The homogenate was centrifuged at 1400 ×g for 3 min at 4°C. Supernatant was transferred to a new 2 ml tube (S1, containing mitochondria and cytosol). The pellet was resuspended in 2 ml isolation buffer and centrifuged at 1400 × g for 3 min and this supernatant was transferred to a new tube (S1′, containing mitochondria and cytosol) and the pellet was discarded. Both supernatant fractions (S1 & S1′) were then topped off with isolation buffer and centrifuged at 13,000 ×g for 10 min. The resultant two pellets were pooled and resuspended in 500 μl isolation buffer (with EGTA) and burst in a nitrogen cell disruption bomb at 4°C for 10 min at 1200 psi to release synaptic mitochondria from synaptosomes. Resultant differential mitochondrial suspension was then centrifuged at 10,000 × g for 10 min. Pellets were re-suspended in~20 μl of isolation buffer (without EGTA). All samples were kept on ice throughout the isolation process. The protein concentrations were determined using BCA protein assay kit (Thermo Scientific, Rockford, IL) by measuring absorbance at 560 nm with a Biotek Synergy HT plate reader (Winooski, Vermont). Note: isolation and measurements of OCRs were completed as quickly as possible after dissecting the tissues (within 5-6 h).
Assessment of mitochondrial respiration
Respiration of mitochondrial samples was measured in terms of mitochondrial oxygen consumption rate (OCR) using a Seahorse Bioscience XF24 Extracellular Flux Analyzer as described previously with slight modifications (Sauerbeck et al., 2011) . Briefly, 24 h prior to each experiment, a 24 well dual-analyzer sensor cartridge (Seahorse Bioscience) was incubated with 1 ml/well of XF Calibrant solution (Seahorse Bioscience) at 37°C in a CO 2 -free incubator (Seahorse Bioscience). On the days of experimentation, either A) pyruvate plus malate plus ADP, B) oligomycin, C) FCCP, or D) rotenone plus succinate were added in ports A-D, respectively, in the Seahorse Flux Pak cartridges to yield final concentrations of 5 mM (pyruvate), 2.5 mM (malate), 1 mM (ADP), 1 μg/ml (oligomycin), 3 μM (FCCP), 100 nM (rotenone), and 10 mM (succinate) and placed into the Seahorse XF24 Flux Analyzer for automated calibration. During the sensor calibration, 50 μl volume of respiration buffer containing 5 μg of mitochondrial protein was added to each well of XF24 V7 cell culture microplates and centrifuged at 2000 rpm for 4 min at 4°C. This was followed by addition of 450 μl of respiration buffer (125 mM KCl, 2 mM MgCl 2 , 2.5 mM KH 2 PO 4 , 20 mM HEPES and 0.1% BSA, pH 7.2) at 37°C (gently added to each well) to make the final assay volume 500 μl per well. Plates were immediately placed into the calibrated Seahorse XF24 Flux Analyzer for assessment of mitochondrial OCR in the presence of substrates and inhibitors in respective ports. The OCR data were analyzed using Excel software package (Microsoft), point by point rates were generated using the AKOS algorithm written by AKOS Gerencser for Seahorse Bioscience. For State III and State V-Complex I, the "middle point" (average) of OCR was generated from 4 time-dependent point-by-point rates for each well sample. Then, three independent middle points were averaged for each sample to generate n = 1 per sample.
Behavioral analyses
Recovery of hind limb motor function was assessed as previously described using the Basso Mouse Scale (BMS) (Basso et al., 2006; Zhang et al., 2015b ). Mice were assessed in an open field apparatus pre-surgically and at 1, 3, 7, 14, 21, and 28 days post-injury (DPI) by two trained observers. Each hind limb was rated independently for movement coordination, and trunk stability, and then averaged to generate a single score on a scale of 0-9. Subscores were also assigned based on frequency of plantar stepping, paw placement, coordination, trunk stability, and tail position. Further assessments of hindlimb function were conducted using the gridwalk test (Cummings et al., 2007; Zhang et al., 2015a) . Briefly, the gridwalk apparatus consists of an elevated horizontal ladder (92 cm × 16.5 cm), with rungs (4 mm in diameter) spaced 1 cm apart, and with a covered black goal box at one end. A high speed camera (Basler scA640) was placed 32 cm under the middle of the ladder. Animals were trained on the apparatus prior to surgery. At 28 DPI, mice were acclimated to the dark box for 3 min, then removed and placed at the opposite, uncovered end of the apparatus and recorded as they crossed the length of the ladder back into the dark box. At least three passes were recorded per animal. Each animal's best pass was chosen for analysis, as determined by overall coordination and uninterrupted movement. The total number of missed steps across 30 rungs was then calculated for each animal's best pass. A missed step was counted when an animals' hindlimb slipped below the horizontal plane of the rungs.
Spinal cord tissue processing
Tissues were processed according to our previously established methods (Zhang et al., 2015b) . Briefly, mice were anesthetized via ketamine (150 mg/kg) and xylazine (10 mg/kg) injection (i.p.). The chest cavity was then opened and animals were perfused transcardially with 0.1 M phosphate-buffered saline (PBS, 7.4 pH) followed by 4% paraformaldehyde (PFA) in 0.1 M PBS. A 1 cm segment of spinal cord centered on the injury site was dissected and post-fixed in PFA for 2 h before being washed overnight in 0.2 M phosphate buffer (7.4 pH). Tissues were cryoprotected in 20% sucrose in 0.1 M phosphate buffer saline at 4°C until the cords sank (3-5 days). Spinal cords were then trimmed to a 6 mm segment centered on the injury epicenter and evenly distributed by experimental group into blocks containing optimal cutting temperature (OCT) compound. The blocks were rapidly frozen then stored at − 80°C. A total of 6 mm spinal cord segment was serially cryosectioned at 10 μm thick coronal sections and every section was collected for a total of 10 slide series, with 6 slides in each series. Therefore, adjacent sections on a slide were separated by 100 μm.
Histology
A modified Eriochrome Cyanine (EC) staining protocol for myelin was used to differentiate between damaged tissue and spared white and grey matter (Rabchevsky et al., 2002; Zhang et al., 2015a) . Briefly, slides were hydrated in dH20, submerged in acetone for 2 min, rehydrated in dH20, and then exposed to serial dilutions of decreasing concentration of EtOH before being incubated in EC for 30 min at room temperature. Excess stain was removed by dH20 washes and slides were differentiated in 0.3% Ammonium Hydroxide. All histological analyses were conducted blindly with respect to treatment condition using a Nikon microscope (Nikon Corporation, Tokyo, Japan) and Scion imaging analysis software (Scion Corporation, Frederick, MD, USA). Identification of intact white and grey matter was based on positive myelin staining as well as comparisons to normal cytoarchitecture. The cross-sectional area of lesion and spared tissues were quantified at 200 μm intervals adjacent to the injury epicenter using the Cavalieri method (Rabchevsky et al., 2002) , for a total of 17 sections per animal.
Immunohistochemistry
Prior to staining, frozen slide-mounted spinal cord sections were thawed for 1 h at 37°C and rinsed with 0.1 M PBS 3 × 5 min. Slides were then incubated at room temperature for 1 h in blocking buffer (0.1 M PBS containing 1% bovine serum albumin, Fisher Scientific, Cat# BP1605), 0.1% Triton X-100 (Sigma-Aldrich, Cat# X-100), 0.1% fish gelatin (Sigma-Aldrich, Cat# G7765), and 5% normal goat (SigmaeAldrich, Cat# G9203). Double immunolabeling for ionized calcium-binding adapter molecule 1 (IBA-1), to evaluate microglia/brain macrophages, and glial fibrillary acidic protein (GFAP), to visualize the astrocytic scar, was performed by incubating slides in chicken anti-GFAP (10 μg/ ml; Aves, Cat# GFAP) and rabbit anti-IBA-1 (1 μg/ml; Wako, Cat# 019-19741) primary antibodies overnight at 4°C in blocking buffer. On the second day, slides were rinsed in 0.1 M PBS followed by a 1 h incubation at room temperature of goat anti-chicken Alexa Flour (AF) 488 (2 μg/ml; Life Technologies A-11039) and goat anti-rabbit AF546 (2 μg/ml; Life Technologies A-11010) secondary antibodies in blocking buffer. Slides were then rinsed in 0.1 M PBS and then were incubated in DAPI (1:95 in 0.1 M PBS; Invitrogen D1306) for 30 min, then rinsed and coverslipped with Immu-Mount (Thermo-Scientific, Waltham, MA).
Microscopy and densitometry
Fluorescent images were captured using a C2+ laser scanning confocal microscope (Nikon Instruments Inc., Melville, NY). For each animal, images were taken at the SCI epicenter (determined by lesion volume estimates and visually confirmed by GFAP staining) as well as 0.6 mm and 1.2 mm, rostral and caudal to the epicenter. A montaged maximum-intensity projection image, consisting of 9 adjacent z-stacks, was generated for each tissue section. When necessary, laser powers were adjusted to capture the full fluorescent intensity range of lightly stained sections. To quantify the proportional area of activated microglia/macrophages, threshold-based analysis of IBA-1 immunoreactivity was performed as described previously with modifications (Donnelly et al., 2009 ). Captured RGB images were opened in the MetaMorph analysis program (Molecular Devices, Sunnyvale, CA) and the perimeter of each section was digitally outlined referencing the cytoarchitecture revealed by GFAP and IBA-1 staining. Next, the AF546 channel was isolated and a threshold selected which identified positive IBA-1 staining above background. For each tissue section, the density of IBA-1 staining was calculated as the ratio of immunoreactive area/region of interest area (entire cross section).
Statistical analyses
All statistical analyses were performed using GraphPad Prism 6 (GraphPad Software, Inc., La Jolla, CA). For mitochondrial bioenergetics, differences between groups were investigated via analysis of variance (ANOVA). Two-way ANOVA were run to analyze differences in tissue morphology across spinal cord levels and to determine changes in BMS data over time. The 28-day BMS subscores and histological assessments were analyzed by one-tailed unpaired Student's t-tests. Correlational analyses were run between histological measures and terminal BMS. When warranted, post-hoc analyses (Bonferroni) were performed. Significance was identified at p b 0.05.
Results
Effects of pioglitazone on mitochondrial bioenergetics
Quantification of mitochondrial respiration in terms of OCR demonstrated that SCI result in significantly decreased State III OCR (F(3,28) = 14.16, p b 0.0001) and State V-I OCR (F(3,28) = 16.10, p b 0.0001) in all injured groups compared to sham (Fig. 1) . Post hoc analysis showed a significant (p b 0.05) decrease in all State III and State V-I in vehicle treated animals compared to sham. Conversely, treatment with pioglitazone at 15 min and 3 h post-injury significantly maintained State III and State V-I OCRs. However, State III and State V-I OCRs remained significantly lower than sham (Fig. 1) .
Effects of pioglitazone on functional recovery
We next assessed the effects of pioglitazone on long-term functional recovery. The data revealed that while both vehicle-and pioglitazonetreated animals demonstrated severe hindlimb paralysis following injury, pioglitazone-treated mice showed improved hindlimb function as early as 7 DPI, (Fig. 2A) . A two-way repeated measures ANOVA revealed main effects of time (F(6,120) = 296.04, p b 0.0001) and treatment condition (F(1,20) = 7.90, p b 0.05). Throughout post-injury assessments pioglitazone-treated mice outperformed vehicle-treated animals, precluding an interaction of the variables (F(5,100) = 1.030, p = 0.4). Furthermore, pioglitazone-treated animals outperformed vehicle-treated mice on multiple terminal assessments of fine locomotor skills. Specifically, Student's t-tests revealed that pioglitazone treatment was associated with substantially higher terminal BMS subscores (p b 0.01, Fig.  2B ). Specifically, differences in terminal BMS subscores are associated with higher number of animals with plantar stepping and coordinated walking pattern, better paw position and tail position above the ground compared to vehicle-treatment, which was revealed in significantly improved performance on the gridwalk assessment (p b 0.05, Fig. 2C ).
Effects of pioglitazone on tissue sparing
Histological assessment of spinal cord sections revealed marked tissue sparing following pioglitazone treatment compared to vehicle, as shown in representative photomicrographs (Fig. 3A) . Analysis of cross-sectional areas revealed increased white matter sparing in pioglitazone-treated group compared to vehicle, particularly in the sections rostral and penumbral to the epicenter (Fig. 3B) . A two-way ANOVA revealed a main effect of treatment (F(1,340) = 16.86, p b 0.0001) and spinal level (F(16,340) = 47.32, p b 0.0001). Similarly, quantification of grey matter area showed increased spared grey matter sparing with pioglitazone treatment, and sparing was most evident in the cross-sections rostral to the epicenter were grey matter was effectively abolished (Fig. 3C) . A two-way ANOVA revealed main effects of treatment (F(1,340) = 5.607, p b 0.05) and spinal level (F(16,340) = 10.58, p b 0.0001). Pioglitazone treatment also resulted in reduced lesioned tissue compared to vehicle-treated animals across nearly all of the cord (Fig.  3D) . Accordingly, a two-way ANOVA revealed a main effect of treatment (F(1,340) = 11.76, p b 0.001) and spinal level (F(16,340) = 76.77, p b 0.0001). Analyses across the entire rostral-caudal extent of injury (3.2 mm of spinal cord) showed that the pioglitazone-treated group had significantly (p b 0.05) less lesion volume, which corresponded to significantly (p b 0.05) greater white and grey matter volumes (Fig.  3E) . Correlational analyses indicate that these anatomical measures significantly correlated with functional outcome measures (Fig. 4) . Collectively, these results show that pioglitazone treatment significantly reduces secondary injury evidenced by increased spared tissue and decreased lesion volume associated with improved functional recovery, specifically hindlimb-forelimb coordination.
Effects of pioglitazone on microglia/macrophage responses
Because pioglitazone may block PPAR on microglia/macrophages, we also examined the effects of pioglitazone treatment on the inflammatory response to SCI. Despite differences in spared tissues, demarcated by GFAP + astroglial scars, IBA-1 + microglia/macrophage responses to SCI appeared the same in vehicle-vs pioglitazone-treated mice at 28 DPI (Fig. 5A) . Such responses were concentrated at the injury epicenter and tapered off at distal regions, and there was a trend for reduced IBA-1 + densities after pioglitazone treatment. However, while a twoway ANOVA revealed a significant main effect of spinal level (F(4,100) = 46.45, p b 0.001), there was no treatment effect (F(1,100) = 2.321, p N 0.05) or treatment × spinal level interaction (F(4,100) = 0.2667, p N 0.05) (Fig. 5B ).
Discussion
Our results demonstrate for the first time that pioglitazone modulates mitochondrial function after SCI and this is associated with improved recovery and tissue sparing. Dosage as well as timings and duration of pioglitazone administration were based on our previous reports in a TBI model (Sauerbeck et al., 2011) . As we hypothesized, by maintaining mitochondrial function acutely after SCI, daily treatment with pioglitazone resulted in increased tissue sparing and functional recovery at later stages. Furthermore, pioglitazone-treated animals displayed significantly improved hindlimb motor recovery throughout the post-injury period and at terminal assessments, which correlated with greater tissue sparing. These behavioral and morphological data are consistent with previous investigations of pioglitazone treatment for SCI in rats (McTigue et al., 2007; Park et al., 2007) , and here we report for the first time that pioglitazone treatment improves gridwalk performance in injured mice. This is an important and refined behavioral consideration, as the gridwalk task discriminates between animals which display the same stepping frequency during open-field assessment (Cummings et al., 2007) . Our seminal finding, however, is that similar treatment in SCI mice significantly protected acute mitochondrial function, both after immediate and 3 h delayed administrations.
Moreover, the tissue sparing afforded by pioglitazone was not associated with decreased levels of microgliosis, again in accordance with findings in a rat SCI model (McTigue et al., 2007) .
Rescuing mitochondrial bioenergetics is linked to improved functional neuroprotection
A growing body of data indicates that preserving mitochondrial bioenergetics following CNS injury is a powerful therapeutic strategy for reducing tissue damage and attenuating locomotor deficits. Multiple interventions which target the mitochondria have shown promise, including administration of mitochondrial uncouplers (Patel et al., 2009) , alternative biofuels (Patel et al., 2010 (Patel et al., , 2012 , and glutathione precursors Patel et al., 2014) . We have previously demonstrated that pioglitazone maintains mitochondrial integrity following TBI (Sauerbeck et al., 2011) and the current study extends these findings, demonstrating that pioglitazone preserves mitochondrial function after SCI as well. Likewise, improving mitochondrial function was associated with increased tissue sparing and improved behavioral performance.
While a number of SCI therapeutics have directly targeted downstream pathophysiological cascades such as oxidative damage, the present study and our previous data suggest that a more promising approach for clinical translation may be targeting upstream processes, specifically mitochondrial respiration. CNS trauma causes an influx of intracellular Ca
2+
, which increases Ca 2+ absorption by mitochondria (Sullivan et al., 2005) and this Ca 2+ sequestering increases production of reactive oxygen species (ROS) (Dugan et al., 1995) . Free radical damage via lipid peroxidation is known to contribute significantly to the propagation of tissue damage after injury (Anderson and Hall, 1993; Hall, 1991; Hall and Braughler, 1993; Springer et al., 1997) . These effects are compounded since oxidative stress instigates pro-inflammatory responses (Christman et al., 2000) . Critically, we have previously demonstrated that maintaining mitochondrial bioenergetics reduces oxidative stress following contusion SCI (Patel et al., 2009) . We have reported that significant mitochondrial dysfunction occurs as early as 6 h post-SCI in rats (Sullivan et al., 2007) , indicating a clinically relevant window of opportunity to rescue mitochondrial dysfunction after injury. This may help to explain, in part, why there were no changes in OCR values after 15 min vs 3 h post-injury administration of pioglitazone. Irrespective of targeting mitochondrial bioenergetics, antagonism of PPAR-γ by itself can reduce pro-inflammatory activities (Drew et al., 2006) . Accordingly, low-dose pioglitazone treatment after SCI in rats (1.5 mg/kg i.p.; four doses at 5 min and 12, 24, and 48 h) significantly reduced the number of activated microglia at 7 days following injury (Park et al., 2007) . In contrast, dosing throughout the first week after SCI (10 mg/kg i.p. at 15 min post-SCI, then There was a significant negative correlation between terminal BMS scores and lesion volume, which corresponded to significant positive correlations between terminal BMS scores and spared grey (B) and white (C) matter. There was also a notable group separation, represented by encircled portions, indicating that pioglitazone (Pio) treatment showed significant neuroprotection associated with higher BMS scores, as compared to vehicle treatment. n = 10-12 per group. every 12 h for 7 days) did not reduce macrophage accumulation in the lesion at 7 DPI (McTigue et al., 2007) . Consistent with the latter results, we detected no significant long-term changes in microglia/macrophage accumulation after pioglitazone treatment (10 mg/kg i.p. at 15 min post-SCI, then daily for 5 days) (Fig. 5) . Notably, the qualitative trends for reduced microglia/macrophage densities following pioglitazone treatment likely reflects increased tissue sparing compared to vehicletreated groups (Fig. 3) .
We have also shown, however, that in the context of TBI pioglitazone treatment reduces microglial activation via PPAR-γ independent mechanisms. More specifically, delivery of a PPAR-γ antagonist (T0070907) in conjunction with pioglitazone elicited similar reduction in activated microglia as pioglitazone treatment alone (Sauerbeck et al., 2011) . This could be due, in part, to reduce mitochondrial dysfunction and consequent tissue damage as a result of pioglitazone treatment leading to a reduction in downstream inflammatory cascades. Likewise, emerging evidence suggests that protective effects of pioglitazone following experimental TBI in mice are not solely related to PPAR-γ-dependent mechanisms (Thal et al., 2011) . Although it has been established in TBI, it will be important to determine if the results of the current study are, in fact, PPAR-γ independent.
Interactions between pioglitazone and mitoNEET
Over a decade ago, pioglitazone was found to bind to a novel outer mitochondrial membrane protein which was then termed "mitoNEET" (Colca et al., 2004) . Evidence now suggests that mitoNEET plays a critical role in energy homeostasis through regulating β-oxidation rates by controlling iron transport into the inter-membrane matrix (Kusminski et al., 2012) . There are important differences between the effects of binding mitoNEET by pioglitazone, compared with other PPAR-γ agonists. For instance, compared with pioglitazone, rosiglitazone has a stronger binding affinity for PPAR-γ and a weaker affinity for mitoNEET, yet has demonstrated less robust neuroprotection following CNS trauma (Berger and Moller, 2002) . Furthermore, data from our TBI experiments suggest that pioglitazone's ability to improve mitochondrial function may be due, in part, to its acute effects on mitochondrial respiration (Sauerbeck et al., 2011) . More specifically, we found that a single injection of pioglitazone 15 min after TBI results in a non-significant trend towards improved mitochondrial function when respiration was measured the next day. Conversely, when an additional injection was given 1 h prior to analyzing the injured tissue, significant improvement in respiration was observed. Collectively, these data point towards our working hypothesis that neuroprotective effects of pioglitazone are at least partially independent of PPAR-γ activation and rely, instead, on direct modification of mitochondrial integrity.
Overall, while this study represents an independent replication of reports that pioglitazone treatment following contusion SCI in rats improves long-term neuroprotection (McTigue et al., 2007; Park et al., 2007) , we further identified that pioglitazone treatment after contusion SCI in mice significantly attenuates acute mitochondrial dysfunction. We also found comparable maintenance of mitochondrial bioenergetics following both early and delayed treatment, setting the stage for testing more delayed administration. Accordingly, ongoing studies are assessing different dosages and clinically relevant therapeutic windows of administration (3-6 h post-injury) to potentially repurpose pioglitazone for neurotrauma and/or develop novel therapeutics that target mitochondrial dysfunction. In addition to planned stereological studies to evaluate neuroprotection, comprehensive assessments of neuroinflammatory markers and microglia/macrophage phenotypes will also help to elucidate the mechanisms by which pioglitazone confers both bioenergetics homeostasis and tissue sparing. 
